| Home | E-Submission | Sitemap | Contact Us |  
J Korean Soc Emerg Med > Volume 35(1); 2024 > Article
Journal of The Korean Society of Emergency Medicine 2024;35(1): 57-66.
코로나-19 백신 예방접종 후 이상반응으로 중증응급진료센터를 내원한 환자분석: 다기관 후향적 관찰연구
조세영1 , 이동언1 , 류현욱1 , 김윤정1 , 박정배1 , 김정호2 , 장태창3 , 진상찬4
1경북대학교 의과대학 응급의학교실
2영남대학교 의과대학 응급의학교실
3대구가톨릭대학교 의과대학 응급의학교실
4계명대학교 의과대학 동산의료원 응급의학교실
Analysis of patients visiting emergency departments with adverse reactions after COVID-19 vaccination: a multicenter retrospective study
Seyeong Jo1 , Dong Eun Lee1 , Hyun Wook Ryoo1 , Yun Jeong Kim1 , Jungbae Park1 , Jung Ho Kim2 , Tae Chang Jang3 , Sang-Chan Jin4
1Department of Emergency Medicine, School of Medicine, Kyungpook National University, Daegu, Korea
2Department of Emergency Medicine, Yeungnam University College of Medicine, Daegu, Korea
3Department of Emergency Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea
4Department of Emergency Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea
Correspondence  Dong Eun Lee ,Tel: 053-200-2812, Fax: 053-200-3870, Email: delee@knu.ac.kr,
Received: March 10, 2023; Revised: July 10, 2023   Accepted: August 16, 2023.  Published online: February 28, 2024.
This study aimed to analyze types and rates of symptoms according to vaccine type and to identify the characteristics of patients who visited emergency departments (EDs) with adverse reactions after coronavirus disease 2019 (COVID-19) vaccination.
The medical records of 1,020 patients who visited the EDs of five participating tertiary hospitals from February 26, 2021 to July 31, 2021, and reported adverse reactions after vaccination with a COVID-19 vaccine to the Korean Disease Control and Prevention Agency or diagnosed with a disease code U129 at time of ED discharge were retrospectively analyzed. Symptoms, examinations, treatments received at EDs, and hospital outcomes were compared with respect to vaccine type.
Of the 1,020 study subjects, 559 received the ChAdOx1-S vaccine, 52 the Ad.26.COV2.S vaccine, 331 the BNT162b2 vaccine, and 77 the mRNA-1273 vaccine. The adenovirus-vectored vaccines (ChAdOx1-S and Ad.26.COV2.S) had the highest myalgia and headache complaint rates during the 24 hours following vaccination. However, the mRNA vaccines (BNT162b2 and mRNA-1273) had the highest chest pain and fever complaint rates at 7 days post-vaccination. Furthermore, 4.7% of the study subjects required hospitalization, and three died during hospitalization.
Patients who visited EDs with adverse reactions after COVID-19 vaccination had various ages and experienced symptoms that depended on vaccine type. Most patients were discharged following ED symptom management, but caution should be exercised as several patients experienced potentially serious adverse events.
Key words: COVID-19 vaccines; Vaccination; Drug-related side effects and adverse reactions
Editorial Office
The Korean Society of Emergency Medicine
TEL: +82-62-226-1780   FAX: +82-62-224-3501   E-mail: dlskdud416@naver.com
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Society of Emergency Medicine.                 Developed in M2PI